Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in late primary spermatocytes | 0.75 |
| chemistry Open Targets | reachable by antibody: serelaxin | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 253 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12026
Sealed predictions
- RXFP2 in dopamine neurons, braak+0.05 (p 0.894) → +0.94 (p 2.1e-4)receipt 12033
Swarm cases
receipt 12033: RXFP2 in dopamine neurons, braak
- power
- full sample +0.58 (p 0.013, n 18), 95% CI +0.15 to +0.82. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.64 (p 0.0040, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.60 (p 0.0080, n 18). not the mix.
- skeptic
- leave-one-out range +0.51 to +0.69, sign flips 0; without severely affected donors +0.58 (p 0.013, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RXFP2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts